The FDA-Approved Oral GLP-1 Wegovy Weight Loss Pill is Now Available in New Jersey The Wegovy Pill for weight loss is now available throughout New Jersey after receiving FDA approval on December 22, 2025
The average weight loss achieved in the Semaglutide FDA study for weight loss was almost 15% of the initial body weight but it is not unusual to see a patient lose 20% of their body weight over the course of the treatment
At six months, the STEP 1 data shows fat mass reduced by 2.1 kg more than lean mass changes would predict
We accept In stock Ships today if ordered by 3 PM EST USA fulfillment COA on request 3rd-party tested 24 h dispatch Certificate of Analysis current lot Verified Batch / Lot # GP-6482-2025 Test date May 4, 2026 Laboratory Freedom Diagnostics Identity / Purity (HPLC) 99.70% Mass confirmation (LC-MS) Match Endotoxin (LAL, USP ) 0.40 EU/mg Residual solvents (USP ) Pass Water content (KF) Pass Description Reviews Retatrutide 10 mg Research Grade (Bulk Vial) Retatrutide is a synthetic triple-agonist research peptide targeting the GLP-1, GIP, and glucagon receptors simultaneously
Even with insurance, weight loss injectables can still cost hundreds of dollars per month
Tirzepatide 10mg: Dual Receptor Agonist (GLP-1 / GIP) Research Compound
